Intraperitoneal Bupivacaine for Pelvic Organ Prolapse
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of 30 mL intraperitoneal Bupivacaine
without epinephrine 0.25% on postoperative pain control in patients undergoing pelvic organ
prolapse repair. The investigators hypothesize that use of intraperitoneal Bupivacaine will
decrease postoperative pain scores and opiate consumption in the postoperative period,
following pelvic organ prolapse repair.